カテゴリ： GlobalData, アイルランド, 企業調査

Allergan Plc (AGN)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Allergan Plc (AGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011458
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月22日
◆ページ数：167
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women’s health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc (AGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Allergan Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Allergan Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Allergan Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Allergan Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Allergan Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Allergan Plc, Medical Equipment, Deal Details 17
Asset Purchase 17
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 17
Allergan Acquires Aline Hyaluronic Acid Thread Technology From Aline Aesthetics 18
LifeCell Acquires Adipose Tissue Injector From TauTona 19
Venture Financing 20
ForSight Vision5 Raises Additional USD4 Million Financingc 20
ForSight Vision5 Raises Additional USD6 Million in Financing 21
Colorescience Raises USD15 Million in Series B Venture Financing 22
ForSight Vision5 Raises US$15 Million In Series C Financing 23
Oculeve Raises US$17 Million In Venture Financing 24
AqueSys Raises US$43.6 Million In Series D Financing 25
Colorescience Raises US$10 Million In Series A Financing 27
ForSight Vision5 Raises US$9 Million In Series B-1 Financing 28
Anterios Raises US$8.5 Million In Venture Financing 29
Anterios Raises US$4.7 Million In Venture Financing 30
Oculeve Raises US$7.6 Million In Venture Financing 31
Topokine Therapeutics Raises Funds Through Venture Financing 32
Colorescience Raises US$15 Million In Venture Financing 33
Regado Biosciences Raises US$51 Million In Series E Financing 34
Oculeve Raises Additional US$0.2 Million In Venture Financing 36
ForSight Vision5 Raises US$8 Million In Venture Financing 37
Uteron Pharma Raises US$10.4 Million In Venture Financing 38
AqueSys Raises US$12 Million In Venture Financing 39
Uteron Pharma Raises US$19 Million In Venture Financing 40
KYTHERA BioPharma Secures US$37.42 Million In Series D Financing Round 41
Anterios Secures US$3.1 Million In Venture Financing 43
Regado Biosciences Secures US$11.6 Million In Financing 44
ForSight Vision5 Raises US$6 Million In Venture Financing 45
Private Equity 46
TPG Capital Acquires Aptalis Pharma from Actavis 46
VMG Partners Invests In Colorescience 47
SRIW Invests US$2 Million In Uteron Pharma 48
Partnerships 49
Medicines360 Enters Into Licensing Agreement With Actavis For Intrauterine Device 49
Enzymatica To Enter Into Licensing Agreement With Actavis For ColdZyme Mouth Spray 50
T2 Biosystems Enters into Agreement with Allergan 51
Allergan Enters into Co-Development Agreement with SonarMD 52
Syneron Medical and Allergan Enter into Agreement 53
Galderma Enters into Agreement with ZELTIQ Aesthetics 54
Advance Medical Enters Into Co-Marketing Agreement With Zeltiq Aesthetics For CoolSculpting System 55
Activaero Enters Into Collaboration With Forest Healthcare 56
Equity Offering 57
Anterios Postpones IPO for up to USD54.6 Million 57
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 58
Actavis Raises USD4.18 Billion in Public Offering of Shares 60
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 62
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 63
Regado Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$43 Million 64
Zeltiq Aesthetics Files Registration Statement For Public Offering Of Securities For US$75 Million 66
Forest Labs Plans Rights Offering Of Common Stock 67
ZELTIQ Aesthetics Completes IPO For US$101 Million 68
Debt Offering 70
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 70
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 71
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 72
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 73
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 74
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 75
Asset Transactions 76
Novadaq to Acquire Rights to SPY Elite System from LifeCell 76
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 77
Acquisition 79
Allergan to Sell 10% Stake in Teva Pharma 79
Allergan Sales to Acquire Keller Medical 80
Allergan Acquires ZELTIQ Aesthetics for USD2.48 Billion 81
Allergan Acquires LifeCell from Acelity for USD2.9 Billion 83
Allergan Acquires Tobira Therapeutics in Tender Offer 85
Carl Icahn Acquires Stake in Allergan 87
Allergan Acquires AqueSys 88
Allergan Acquires Northwood Medical 89
Allergan Acquires Oculeve 90
Actavis Acquires Allergan for USD70.5 Billion 91
Actavis Completes Acquisition of Forest Labs for USD28 Billion 93
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 95
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 97
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 98
Watson Pharma Acquires Uteron Pharma, Women’s Health Company, For Up To US$305 Million 99
SkinMedica Acquires Colorescience, Maker Of Skincare Products 101
Allergan Acquires Precision Light For US$17.9 Million 102
Allergan Completes Acquisition Of Alacer Biomedical 103
Forest Labs Completes Acquisition Of Clinical Data 104
Allergan Plc – Key Competitors 106
Allergan Plc – Key Employees 107
Allergan Plc – Locations And Subsidiaries 108
Head Office 108
Other Locations & Subsidiaries 108
Recent Developments 116
Strategy And Business Planning 116
Aug 09, 2016: EDA Board Acts to Encourage Global Pharmaceutical Company Allergan to Expand in New Jersey 116
Financial Announcements 117
Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion 117
Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion 121
May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 125
Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 129
Nov 02, 2016: Allergan Reports Third Quarter 2016 Continuing Operations Performance with GAAP Net Revenues of $3.6 Billion; Announces Accelerated Share Repurchase, Initiation of Cash Dividend 133
Aug 08, 2016: Allergan Reports Strong Second Quarter 2016 Continuing Operations Performance with Net Revenues of $3.7 Billion 137
May 10, 2016: Allergan Reports Strong First Quarter 2016 Continuing Operations Performance with 48% Increase in Net Revenue to $3.8 Billion and 15% Growth in Non-GAAP Diluted EPS to $3.04 141
Corporate Communications 144
Dec 18, 2017: Allergan Announces Promotion of Wayne Swanton to Executive Vice President, Global Operations 144
Sep 11, 2017: The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts 145
Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 146
Apr 10, 2017: Allergan Receives 2017 ENERGY STAR Partner of the Year – Sustained Excellence Award from U.S. Environmental Protection Agency 147
Apr 06, 2017: Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy 148
Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 149
Nov 14, 2016: Adriane M. Brown to Join Allergan Board of Directors 150
Oct 26, 2016: Allergan Announces Changes to Board Leadership 151
Feb 08, 2016: Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction 152
Product News 153
Nov 08, 2017: Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans 153
Oct 11, 2017: Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference 154
Oct 05, 2017: Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago 155
May 04, 2017: Allergan to Present New Data at the 2017 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting in San Diego 157
Jan 05, 2017: Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference and Provides Preliminary Comments on 2017 Outlook 158
May 04, 2016: Allergan Presents Data at the 2016 American Society of Cataract and Refractive Surgery Symposium & Congress in New Orleans 159
03/03/2016: Allergan Launches Bold Access To LILETTA (levonorgestrel-releasing intrauterine system) 160
Other Significant Developments 161
Sep 25, 2017: New Study Showcases Economic Impact of Allergan Operations on French Economy 161
Sep 14, 2017: Industry Leaders Allergan and Sientra Invest in The American Society for Aesthetic Plastic Surgery for Breast Implant Research 162
Sep 12, 2017: Allergan Launches New Brilliant Distinctions Patient Loyalty Program 163
Oct 13, 2016: Allergan Partners with SonarMD to Develop Innovative IBS-D Patient Engagement Platform for Better Identification and Care of IBS-D Patients 164
Oct 05, 2016: New Study Showcases Economic Impact of Allergan’s Operations on New Jersey Economy 165
Appendix 167
Methodology 167
About GlobalData 167
Contact Us 167
Disclaimer 167

List of Tables
Allergan Plc, Medical Equipment, Key Facts, 2016 2
Allergan Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Allergan Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Allergan Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Allergan Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Allergan Plc, Deals By Market, 2011 to YTD 2017 11
Allergan Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 17
Allergan Acquires Aline Hyaluronic Acid Thread Technology From Aline Aesthetics 18
LifeCell Acquires Adipose Tissue Injector From TauTona 19
ForSight Vision5 Raises Additional USD4 Million Financingc 20
ForSight Vision5 Raises Additional USD6 Million in Financing 21
Colorescience Raises USD15 Million in Series B Venture Financing 22
ForSight Vision5 Raises US$15 Million In Series C Financing 23
Oculeve Raises US$17 Million In Venture Financing 24
AqueSys Raises US$43.6 Million In Series D Financing 25
Colorescience Raises US$10 Million In Series A Financing 27
ForSight Vision5 Raises US$9 Million In Series B-1 Financing 28
Anterios Raises US$8.5 Million In Venture Financing 29
Anterios Raises US$4.7 Million In Venture Financing 30
Oculeve Raises US$7.6 Million In Venture Financing 31
Topokine Therapeutics Raises Funds Through Venture Financing 32
Colorescience Raises US$15 Million In Venture Financing 33
Regado Biosciences Raises US$51 Million In Series E Financing 34
Oculeve Raises Additional US$0.2 Million In Venture Financing 36
ForSight Vision5 Raises US$8 Million In Venture Financing 37
Uteron Pharma Raises US$10.4 Million In Venture Financing 38
AqueSys Raises US$12 Million In Venture Financing 39
Uteron Pharma Raises US$19 Million In Venture Financing 40
KYTHERA BioPharma Secures US$37.42 Million In Series D Financing Round 41
Anterios Secures US$3.1 Million In Venture Financing 43
Regado Biosciences Secures US$11.6 Million In Financing 44
ForSight Vision5 Raises US$6 Million In Venture Financing 45
TPG Capital Acquires Aptalis Pharma from Actavis 46
VMG Partners Invests In Colorescience 47
SRIW Invests US$2 Million In Uteron Pharma 48
Medicines360 Enters Into Licensing Agreement With Actavis For Intrauterine Device 49
Enzymatica To Enter Into Licensing Agreement With Actavis For ColdZyme Mouth Spray 50
T2 Biosystems Enters into Agreement with Allergan 51
Allergan Enters into Co-Development Agreement with SonarMD 52
Syneron Medical and Allergan Enter into Agreement 53
Galderma Enters into Agreement with ZELTIQ Aesthetics 54
Advance Medical Enters Into Co-Marketing Agreement With Zeltiq Aesthetics For CoolSculpting System 55
Activaero Enters Into Collaboration With Forest Healthcare 56
Anterios Postpones IPO for up to USD54.6 Million 57
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 58
Actavis Raises USD4.18 Billion in Public Offering of Shares 60
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 62
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 63
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 64
Zeltiq Aesthetics Files Registration Statement For Public Offering Of Securities For US$75 Million 66
Forest Labs Plans Rights Offering Of Common Stock 67
ZELTIQ Aesthetics Completes IPO For US$101 Million 68
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 70
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 71
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 72
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 73
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 74
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 75
Novadaq to Acquire Rights to SPY Elite System from LifeCell 76
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 77
Allergan to Sell 10% Stake in Teva Pharma 79
Allergan Sales to Acquire Keller Medical 80
Allergan Acquires ZELTIQ Aesthetics for USD2.48 Billion 81
Allergan Acquires LifeCell from Acelity for USD2.9 Billion 83
Allergan Acquires Tobira Therapeutics in Tender Offer 85
Carl Icahn Acquires Stake in Allergan 87
Allergan Acquires AqueSys 88
Allergan Acquires Northwood Medical 89
Allergan Acquires Oculeve 90
Actavis Acquires Allergan for USD70.5 Billion 91
Actavis Completes Acquisition of Forest Labs for USD28 Billion 93
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 95
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 97
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 98
Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To US$305 Million 99
SkinMedica Acquires Colorescience, Maker Of Skincare Products 101
Allergan Acquires Precision Light For US$17.9 Million 102
Allergan Completes Acquisition Of Alacer Biomedical 103
Forest Labs Completes Acquisition Of Clinical Data 104
Allergan Plc, Key Competitors 106
Allergan Plc, Key Employees 107
Allergan Plc, Other Locations 108
Allergan Plc, Subsidiaries 108

★海外企業調査レポート[Allergan Plc (AGN)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Ergon Energy Corporation Limited：企業の戦略・SWOT・財務分析
    Ergon Energy Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Ergon Energy Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • B. Braun Melsungen AG：医療機器：M&Aディール及び事業提携情報
    Summary B. Braun Melsungen AG (B. Braun) develops, manufactures and distributes medical technology and pharmaceutical products, and provides medical services worldwide. The company’s major products include solutions and disposables for infusion, nutrition and pain therapy, infusion pumps and systems …
  • Brinker International, Inc.：企業の戦略・SWOT・財務分析
    Brinker International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Brinker International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • NetSuite Inc：企業の戦略的SWOT分析
    NetSuite Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • OPG Power Ventures Plc (OPG)：電力：M&Aディール及び事業提携情報
    Summary OPG Power Ventures Plc (OPG) is an electric utility. It develops, owns, operates, and maintains private sector power projects in India. The company produces electricity from coal source. OPG operates coal-fired power plants in Tamil Nadu and Gujarat. It sells the electricity generated from i …
  • Mahanagar Telephone Nigam Ltd (MTNL)：企業の財務・戦略的SWOT分析
    Mahanagar Telephone Nigam Ltd (MTNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Agway Energy Services, LLC：企業の戦略的SWOT分析
    Agway Energy Services, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Surge Global Energy Inc：石油・ガス：M&Aディール及び事業提携情報
    Summary Surge Global Energy Inc (Surge Global) is an independent oil and gas exploration, production and trading company. The company acquires, finance and develops oil and gas properties. Its energy and metal commodities comprise natural gas, crude oil, coal, electricity, refined petroleum products …
  • Husky Energy Inc：企業の戦略・SWOT・財務情報
    Husky Energy Inc - Strategy, SWOT and Corporate Finance Report Summary Husky Energy Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Genesis Energy LP (GEL)：企業の財務・戦略的SWOT分析
    Genesis Energy LP (GEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Cleco Corporate Holdings, Llc：企業の戦略・SWOT・財務分析
    Cleco Corporate Holdings, Llc - Strategy, SWOT and Corporate Finance Report Summary Cleco Corporate Holdings, Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Cardinal Ethanol LLC (CRDE)：企業の戦略的SWOT分析
    Cardinal Ethanol LLC (CRDE) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • ECO Animal Health Group Plc (EAH)：企業の財務・戦略的SWOT分析
    Summary ECO Animal Health Group Plc (ECO) is a veterinary products manufacturer that offers therapeutic products. The company develops, registers and markets pharmaceutical products and chemicals for animal health markets. ECO produces proprietary patented drugs that are used for the treatment of re …
  • Chiyoda Corporation：企業の戦略・SWOT・財務分析
    Chiyoda Corporation - Strategy, SWOT and Corporate Finance Report Summary Chiyoda Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Apache Corp (APA)：企業の財務・戦略的SWOT分析
    Apache Corp (APA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Fondazione Telethon：製薬・医療：M&Aディール及び事業提携情報
    Summary Fondazione Telethon (Telethon) is a non-profit healthcare organization that funds and invests for projects in the area of biomedical research on genetic diseases. The organization develops projects by offering support services for increasing the horizons of therapeutic application to new res …
  • Phillips-Medisize Corp：医療機器：M&Aディール及び事業提携情報
    Summary Phillips-Medisize Corp (Phillips-Medisize) is a provider of outsourced design and manufacturing services to medical, defense, consumer, and automotive markets. The company operates as a subsidiary of Molex LLC. It offers a broad range of pre-production and production services. The company of …
  • Golden Agri-Resources Ltd：戦略・SWOT・企業財務分析
    Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Tyler Technologies Inc (TYL)：企業の財務・戦略的SWOT分析
    Tyler Technologies Inc (TYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Tivo Corporation：戦略・SWOT・企業財務分析
    Tivo Corporation - Strategy, SWOT and Corporate Finance Report Summary Tivo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆